00:22 , Jul 6, 2017 |  BC Extra  |  Clinical News

BioNTech, Neon teams report personalized cancer vaccine data

In papers published in Nature, two groups each reported results from Phase I studies showing responses to personalized neoantigen cancer vaccines to treat melanoma. The groups included a team from BioNTech AG (Mainz, Germany), and...
20:06 , Apr 28, 2017 |  BC Week In Review  |  Company News

Agenus restructuring news

In March, Agenus said it will reduce headcount by about 50. The company, which had 255 employees at Feb. 28, did not respond to inquiries. Agenus said it will focus on the development of its immuno-oncology...
15:30 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

AutoSynVax: Ph I started

Agenus began an open-label, U.S. Phase I trial to evaluate 240 µg subcutaneous AutoSynVax plus the company's QS-21 Stimulon adjuvant given every 2 weeks for up to 1 year in about 20 patients. Agenus Inc. (NASDAQ:AGEN),...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
23:22 , Feb 23, 2017 |  BC Extra  |  Company News

Agenus pointing to its checkpoint inhibitors

Agenus Inc. (NASDAQ:AGEN) is looking past the demise of its Prophage G-200 vaccine in brain cancer and pointing investors to upcoming milestones for its checkpoint inhibitor combinations. The company’s shares fell 16% on Wednesday after...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Company News

PhosImmune, Agenus deal

Agenus acquired cancer vaccine company PhosImmune for $2.5 million in cash up front and $7.4 million in shares of Agenus common stock. PhosImmune shareholders are also eligible for up to $35 million in milestones, payable...